Mike Peters, of Dyserth, was admitted to The Christie hospital in Manchester in January. The father-of-two, who is married to Jules, has been undergoing Chimeric Antigen Receptor T-Cell Therapy (CAR-T ...

Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of patients with relapsed or refractory or R/R, follicular ...

Bispecific antibodies offer outpatient treatment options, increasing access to advanced therapies in community settings and reducing the burden of travel for patients. Recent approvals and ...

Results from the Phase Ib/II EPCORE NHL-2 trial demonstrate that the combination of epcoritamab, a CD3xCD20 bispecific antibody, and GemOx (gemcitabine plus oxaliplatin) offers deep and durable ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

Genmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration ...